LivaNova - Page title

Form 10-K Announcement

Mar 4, 2016

4 March 2016

LIVANOVA PLC

LivaNova PLC (the “Company” or “LivaNova”) today announced that it filed a transitional Report on Form 10-K/T under the U.S. Securities Exchange Act of 1934, as amended, for LivaNova’ for the period April 24, 2015 to December 31 2015 (“Form 10-K”) with the U.S. Securities and Exchange Commission (the “SEC”) on 4 March 2016. The Form 10-K can be found on the SEC’s website at www.sec.gov and in the Investor Relations section of the Company’s website at www.livanova.com.

A copy of the Form 10-K has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at http://www.morningstar.co.uk/uk/NSM.

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit www.livanova.com, or contact:


Investor Relations:
Vivid Sehgal
Chief Financial Officer

e-mail: investor.relations@livanova.com

Investor Relations and Media:
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7441
Fax: +1 (281) 853-2537
e-mail: corporate.communications@livanova.com

- End -